Bayer's Roundup Reckoning and Pharma Payoff Converge on a Single December Deadline

Bayer investors have two clocks running at once, and both are approaching milestones that will shape how the stock is valued into 2027. One is legal, with a courtroom in Missouri weighing a proposed $7.25 billion settlement of the long-running Roundup litigation. The other is commercial, where a pair of fresh drug approvals and an upgraded outlook are waiting to be converted into hard revenue.

CEO Bill Anderson told investors on November 3 that he expects a judicial decision on the Roundup settlement before Christmas, according to Reuters. That timeline matters because the proposed accord, currently under review by the Missouri court, sits at the center of how the market prices Bayer's legal exposure. A ruling that upholds the framework would make the financial burden easier to model — provided the terms actually deliver the predictability investors have been promised.

A Court Date and a Guidance Raise, Side by Side

The legal question and the operating story are not separate threads. They are the two halves of the same investment case, and the third quarter gave both something to work with. Bayer reported revenue of EUR 10.053 billion for Q3 2026 and EBITDA before special items of EUR 1.615 billion, with Pharmaceuticals driving the growth.

Days after those numbers landed, the company lifted its full-year targets across several measures: the Pharmaceuticals margin, group EBITDA before special items, and free cash flow. The breadth of that upgrade is what stands out. Profitability and cash generation were raised together, giving the improved expectations a firmer footing than a single-metric beat would have provided.

For 2026, Bayer now points to a Pharmaceuticals margin of 25% to 27% and group EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion. Those figures turn the pharma narrative into something measurable, and they set the bar against which the next set of results will be judged.

Should investors sell immediately? Or is it worth buying Bayer?

Two Approvals, One Question

The pipeline delivered as well. On November 4, Bayer disclosed Chinese approval for Sevabertinib as a first-line treatment for adults with advanced HER2-mutated non-small cell lung cancer. A day later, the FDA cleared Asundexian under the brand name Sunharbo for reducing the risk of recurrent stroke when used alongside an antiplatelet therapy. Bayer describes it as the world's first approved factor XIa inhibitor, with the Phase III OCEANIC-STROKE trial as its foundation.

Regulatory wins are only the opening act. The real test is whether these products generate sales and earnings that show up in the group's financials. That transition — from laboratory and approval letter to the income statement — is where the pharma story will either hold up or fall short.

Analysts Split on How Much Credit to Give

Reactions on the sell side illustrate just how much room there is for disagreement. Deutsche Bank Research raised its price target to EUR 65 and kept a buy rating, citing a third quarter that beat expectations and higher estimates for the closing quarter, both powered by Pharmaceuticals. Jefferies, by contrast, stayed at hold with a EUR 48.50 target. Analyst Michael Leuchten called the Asundexian approval expected, while noting that the risk to Bayer's pharma pipeline had fallen considerably.

The share price has already done a lot of the work: the stock is up 53% since the start of the year. That gain raises the stakes for the next proof point. Operational strength in Pharmaceuticals supports the bull case only for as long as it keeps delivering against expectations that have moved higher.

What December and February Must Settle

Two dates now anchor the calendar. Before Christmas, the Missouri court's decision on the $7.25 billion Roundup settlement will determine whether the legal overhang becomes more calculable. Then, on February 24, 2027, Bayer publishes its full-year 2026 results — the first comprehensive read on whether the raised guidance and the new approvals have translated into durable earnings.

A settlement that holds, combined with delivery on the upgraded targets, would give Bayer a sturdier foundation for its valuation. Until then, the case rests on two things moving in tandem: demonstrable commercial strength and a legal framework that investors can finally price with confidence.

Ad

Bayer Stock: New Analysis - 12 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...